[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603233":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":39,"centralContacts":43,"locations":50,"responsibleParty":67,"collaborators":70,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":26,"enrollmentInfo":84,"targetDuration":26,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":98,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Université de Sherbrooke","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Group with Type 1 Diabetes","EXPERIMENTAL","Participants will undergo a 9-hour postprandial metabolic study",[13,14,15,16],"Diagnostic Test: Imaging PET\u002FMRI","Diagnostic Test: Stable isotope infusions","Diagnostic Test: meal test","Diagnostic Test: Indirect calorimetry",{"label":18,"type":10,"description":11,"interventionNames":19},"Group without Type 1 Diabetes",[13,14,15,16],[21,27,31,35],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIAGNOSTIC_TEST","Imaging PET\u002FMRI","MRI using 1H-MRS and Dixon sequences on a 3 T clinical MRI system (Ingenia, Philips Healthcare, Best, the Netherlands) will be performed.\n\n\\[11C\\]-palmitate: 1 x i.v. injection of 175 MBq followed by TEP imaging. \\[18F\\]-FTHA: oral administration of 75 MBq followed by TEP imaging.",[9,18],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Stable isotope infusions","\\[6,6 D2\\]-glucose infusion (0.22 µmol\u002Fkg\u002Fmin, preceded by a bolus of 22 µmol\u002Fkg) will start from -180 until time + 360.\n\n\\[1,1,2,3,3-2H\\]-glycerol (0.05 µmol\u002Fkg\u002Fmin.) and of \\[7,7,8,8-2H\\] palmitate (0.01 µmol\u002Fkg\u002Fmin) will start from time -60 until time +360.",[9,18],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"meal test","A liquid meal will be administered at time 0. The liquid meal (400 ml) energy breakdown is 50% (101g) from glucose, 33% (31g) from fat, and 17% (40g) from protein; participants will consume the 400 ml in 4 aliquots of 100 ml over 20 min, supplemented with 0.9 g of U-\\[13C\\]-glucose and 9 μmol\u002Fkg lean mass of \\[U-13C\\]-palmitate.",[9,18],{"type":22,"name":36,"description":37,"armGroupLabels":38,"otherNames":26},"Indirect calorimetry","Indirect calorimetry (Vmax Series from Vyaire medical, licence # 22536), measured during10 minutes, every hour.",[9,18],[40],{"name":41,"affiliation":5,"role":42},"André C Carpentier, MD","PRINCIPAL_INVESTIGATOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"Frédérique Frisch","CONTACT","+1-819-346-1110","12394","frederique.frisch@usherbrooke.ca",[51],{"facility":52,"status":26,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Centre de recherche du CHUS","Sherbrooke","Quebec","J1H 5N4","Canada","CA",{"type":59,"coordinates":60},"Point",[61,62],-71.89908,45.40008,{"lat":62,"lon":61},[65,66],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},{"name":41,"role":42,"phone":26,"phoneExt":26,"email":26},{"type":42,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"André Carpentier","Tenure professor",[71],{"name":72,"class":6},"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","100603233","how-abnormal-function-of-fat-tissue-in-type-1-diabetes-contributes-to-fat-in-the-liver-100603233",false,"NCT07133854","How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver","The Impact of Adipose Tissue Insulin Resistance and Abdominal Obesity on Hepatic Fatty Acid Metabolism in Type 1 Diabetes","AGL14","Inclusion Criteria:\n\n* 16 individuals living with T1D and abdominal obesity, as defined by the International Diabetes Federation country\u002Fethnic group-specific criteria (https:\u002F\u002Fwww.idf.org\u002Fe-library\u002Fconsensus-statements\u002F60- \\[1\\]. Treatment for T1D will be intensive insulin therapy on continuous pump perfusion with continuous glucose monitoring.\n* 16 individuals with normoglycemia (i.e., HbA1c below 6.0%) matched for sex, age (± 5 years), waist circumference (± 3 cm), and menopausal status.\n\nExclusion Criteria:\n\n* less than 70% of time in glycemic range (for T1D);\n* history of primary dyslipidemia (LDL-cholesterol over 5 mmol\u002FL or TG over 10 mmol\u002FL) or uncontrolled high blood pressure (over 160\u002F100 mmHg) precluding the withdrawal of lipid lowering and anti-hypertensive agents as per protocol;\n* presence of overt cardiovascular, liver or renal disease (except microalbuminuria without reduced kidney function), or other uncontrolled medical conditions;\n* use of any medication other than insulin that may affect lipid or carbohydrate metabolism and that cannot be stopped prior to testing;\n* current or planned pregnancy within the next 6 months;\n* any contraindication to MRI.\n* Being allergic to eggs\n* Smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day\n* Having participated to a research study with exposure to radiation in the last year before the start of the study",true,"ALL","21 Years",{"count":85,"type":86},32,"ESTIMATED","INTERVENTIONAL",[89],"NA","Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.",[92,93,94],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Non-Alcoholic Steato-Hepatitis (NASH)","Type 1 Diabetes Mellitus",[96,97],"abdominal obesity","Adipose tissue insulin resistance","NOT_YET_RECRUITING","2025-08-13",{"date":101,"type":102},"2025-08-21","ACTUAL",{"date":104,"type":86},"2026-09",{"date":106,"type":86},"2028-12",{"name":5,"class":6},1]